Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats amyotrophic lateral sclerosis (ALS). Sold as Rilutek, Tiglutik, Exservan. Every FDA application for this active ingredient: 3 branded and 9 generic.
As of Nov 14, 2026, FDA lists 12 applications for Riluzole (sold as Rilutek, Tiglutik, Exservan), first approved Dec 12, 1995, with 1 new use approved and 0 published complete response letters.
First approved: Dec 12, 1995
Applications: 12
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $14.0M
First approved in the EU: Jun 10, 1996
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Teglutik
Part D
$7.2M
+98%
360
Riluzole
Part D
$6.8M
-18%
10,580
Exservan
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
RILUZOLE 50 MG TABLET: $0.291 per unitGeneric · -4% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Impax Labs
Sun Pharm Inds Ltd